New research builds on Nobel-winning immune checkpoint blockade work
Immunotherapy’s promise in the fight against cancer drew international attention after two scientists won a Nobel Prize this year for unleashing the ability of the immune system to eliminate tumor cells.
But their approach, which keeps cancer cells from shutting off the immune system’s powerful T-cells before they can fight tumors, is just one way to use the body’s natural defenses against deadly disease. A team of Vanderbilt University bioengineers today announced a major breakthrough in another: penetrating tumor-infiltrating immune cells and flipping on a switch that tells them to start fighting. The team designed a nanoscale particle to do that and found early success using it on human melanoma tissue.
“Tumors are pretty conniving and have evolved many ways to evade detection from our immune system,” said John T. Wilson, assistant professor of chemical and biomolecular engineering and biomedical engineering. “Our goal is to rearm the immune system with the tools it needs to destroy cancer cells.
“Checkpoint blockade has been a major breakthrough, but despite the huge impact it continues to have, we also know that there are a lot of patients who don’t respond to these therapies. We’ve developed a nanoparticle to find tumors and deliver a specific type of molecule that’s produced naturally by our bodies to fight off cancer.”
That molecule is called cGAMP, and it’s the primary way to switch on what’s known as the stimulator of interferon genes (STING) pathway: a natural mechanism the body uses to mount an immune response that can fight viruses or bacteria or clear out malignant cells. Wilson said his team’s nanoparticle delivers cGAMP in a way that jump-starts the immune response inside the tumor, resulting in the generation of T-cells that can destroy the tumor from the inside and also improve responses to checkpoint blockade.
While the Vanderbilt team’s research focused on melanoma, their work also indicates that this could impact treatment of many cancers, Wilson said, including breast, kidney, head and neck, neuroblastoma, colorectal and lung cancer.
His findings appear today in a paper titled “Endosomolytic Polymersomes Increase the Activity of Cyclic Dinucleotide STING Agonists to Enhance Cancer Immunotherapy” in the journal Nature Nanotechnology.
Daniel Shae, a Ph.D. student on Wilson’s team and first author of the manuscript, said the process began with developing the right nanoparticle, built using “smart” polymers that respond to changes in pH that he engineered to enhance the potency of cGAMP. After 20 or so iterations, the team found one that could deliver cGAMP and activate STING efficiently in mouse immune cells, then mouse tumors and eventually human tissue samples.
“That’s really exciting because it demonstrates that, one day, this technology may have success in patients,” Shae said.
The Latest on: Cancer Immunotherapy
[google_news title=”” keyword=”cancer Immunotherapy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Cancer Immunotherapy
- Swiss cancer research could ‘boost’ immunotherapyon February 4, 2023 at 12:17 pm
Swiss researchers have made major advances in cancer immunotherapy but bringing these to patients faces challenges.
- Immunotherapy is the ray of hope for cancer warriors across Indiaon February 3, 2023 at 10:15 pm
While the first immunotherapy drug came into the market in the USA in 2011, being relatively new, many trials are ongoing. At present, immunotherapy can be treated to cure bladder cancer, breast ...
- Study Finds Link Between Tumor Microbiome and Immunotherapy Outcomes in Soft Tissue Sarcomaon February 3, 2023 at 7:45 am
The study suggests there is measurable amount of microbiome within the soft tissue sarcoma tumor environment, which was previously thought to be sterile.
- Why Isn't Immunotherapy More Effective Against Lung Cancer?on February 3, 2023 at 2:14 am
Bacteria naturally found in the lungs could be responsible for dampening the immune response to cancer after immunotherapy, reducing its effectiveness, reports new study.
- SLU finds cancer immunotherapy does not interfere with COVID-19 immunity in vaccinated patientson February 2, 2023 at 4:58 pm
St. Louis University’s researched showed that cancer immunotherapy does not interfere with COVID-19 immunity in previously vaccinated patients.
- Why lung cancer doesn't respond well to immunotherapyon February 2, 2023 at 1:43 pm
Immunotherapy—drug treatment that stimulates the immune system to attack tumors—works well against some types of cancer, but it has shown mixed success against lung cancer.
- MD Anderson Cancer Center partners with biotech co. to improve cancer immunotherapy responseon February 2, 2023 at 12:12 pm
According to Wargo, only a minority of cancer patients receive long-term benefits from immunotherapy, with effectiveness varying based on cancer type. Baltimore-based Johns Hopkins Medicine estimated ...
- Despite Rapid Increase in Immunotherapy Use for Lung Cancer, Survival Benefit for Older Patients Is Modeston February 2, 2023 at 11:59 am
Since 2015, the use of immunotherapies has increased for both young and older patients, but the survival benefit is more evident in younger patients, findings demonstrated.
- Immunotherapy: Harnessing the body's immune system to fight canceron February 2, 2023 at 10:17 am
Cutting-edge immunotherapy can add high-quality years to the lives of people with advanced cancer but there can be side effects and not all tumours respond to the treatment ...
- Supercharge your immunity: How immunotherapy can better train your immune system when battling with canceron February 2, 2023 at 6:23 am
Sunway Medical Centre Velocity (SMCV) in a statement said cancer-fighting technology has improved in leaps and bounds in recent years, and one newer technology that has been known to be effective in ...
via Bing News